- Home
- CIFR vs RYTM Comparison
CIFR vs RYTM Comparison
Compare CIFR & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CIFR | RYTM |
|---|---|---|
| Founded | 2021 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.6B | 6.4B |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | CIFR | RYTM |
|---|---|---|
| Price | $16.19 | $113.41 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 11 | 13 |
| Target Price | $25.60 | ★ $127.31 |
| AVG Volume (30 Days) | ★ 39.8M | 966.4K |
| Earning Date | 11-03-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $206,454,000.00 | $174,334,000.00 |
| Revenue This Year | $69.76 | $47.34 |
| Revenue Next Year | $57.25 | $57.18 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 35.41 | ★ 54.92 |
| 52 Week Low | $1.86 | $45.91 |
| 52 Week High | $25.52 | $122.20 |
Technical Indicators
Market Signals| Indicator | CIFR | RYTM |
|---|---|---|
| Relative Strength Index (RSI) | 45.94 | 58.65 |
| Support Level | $13.67 | $109.99 |
| Resistance Level | $16.00 | $115.05 |
| Average True Range (ATR) | 1.70 | 5.10 |
| MACD | -0.39 | 0.69 |
| Stochastic Oscillator | 35.29 | 59.67 |
Price Performance
Historical ComparisonAbout CIFR Cipher Mining Inc.
Cipher Mining Inc ia an emerging technology company that operates in the Bitcoin mining ecosystem in the United States. The company is developing a cryptocurrency mining business, specializing in Bitcoin. The company is expanding and strengthening the Bitcoin network's critical infrastructure in the United States.
About RYTM Rhythm Pharmaceuticals Inc.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.